These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30706335)

  • 1. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
    Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
    Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
    Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
    Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
    Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer.
    Zhao H; Ma J; Lei T; Ma W; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):810-817. PubMed ID: 30374653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting.
    Sun X; Yu Y; Ma L; Xue X; Gao Z; Ma J; Zhang M
    Invest New Drugs; 2020 Jun; 38(3):722-732. PubMed ID: 31267380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.
    Ma J; Han H; Liu D; Li W; Feng H; Xue X; Wu X; Niu G; Zhang G; Zhao Y; Liu C; Tao H; Gao B
    PLoS One; 2013; 8(8):e73261. PubMed ID: 24015299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting bladder cancer using activated T cells armed with bispecific antibodies.
    Ma J; Ge J; Xue X; Xiu W; Ma P; Sun X; Zhang M
    Oncol Rep; 2018 Mar; 39(3):1245-1252. PubMed ID: 29328392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo.
    Han H; Ma J; Zhang K; Li W; Liu C; Zhang Y; Zhang G; Ma P; Wang L; Zhang G; Tao H; Gao B
    Int J Oncol; 2014 Dec; 45(6):2446-54. PubMed ID: 25242665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.
    Davol PA; Smith JA; Kouttab N; Elfenbein GJ; Lum LG
    Clin Prostate Cancer; 2004 Sep; 3(2):112-21. PubMed ID: 15479495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells.
    Sun X; Zhao J; Ma L; Sun X; Ge J; Yu Y; Ma J; Zhang M
    Invest New Drugs; 2021 Feb; 39(1):24-33. PubMed ID: 32770284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.
    de Jong G; Bartels L; Kedde M; Verdegaal EME; Gillissen MA; Levie SE; Cercel MG; van Hal-van Veen SE; Fatmawati C; van de Berg D; Yasuda E; Claassen YB; Bakker AQ; van der Burg SH; Schotte R; Villaudy J; Spits H; Hazenberg MD; van Helden PM; Wagner K
    Cancer Immunol Immunother; 2021 Jun; 70(6):1569-1581. PubMed ID: 33225419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.
    Lum LG; Ramesh M; Thakur A; Mitra S; Deol A; Uberti JP; Pellett PE
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1012-22. PubMed ID: 22313635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo.
    Ma P; He Q; Li W; Li X; Han H; Jin M; Liu C; Tao H; Ma J; Gao B
    Oncol Rep; 2015 Nov; 34(5):2567-75. PubMed ID: 26323605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
    Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
    J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody.
    Ma W; Ma J; Lei T; Zhao M; Zhang M
    J Cancer; 2019; 10(21):5153-5161. PubMed ID: 31602268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
    Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
    Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
    Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
    Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
    Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.